Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study.  

Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). 

The AI tools will be used to quantify changes in multiple imaging biomarkers, as well as changes in fibrosis volume in localised sections of the lungs. 

CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF. 

AURORA is a randomised, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of CAL101 in patients with IPF.  

The study aims to enrol 150 individuals with IPF across more than 50 sites, primarily in the US, UK, EU, Turkey and South Korea. The study’s primary endpoint is lung function, measured by forced vital capacity, or how much air can forcibly be exhaled, versus an individual’s baseline. 

Jonas Hallén, Co-Founder and Chief Medical Officer, Calluna Pharma, said: “The recently announced dosing of a first patient in our Phase II AURORA study,1 marks a significant milestone for Calluna, an important step forward in our effort to develop novel therapies for IPF and other fibrotic and inflammatory disorders. The AURORA study is designed to demonstrate CAL101’s potential to impact lung function decline and Qureight’s imaging technology will offer critical insights as we measure these key outcomes.”

Diana Turner, Senior Digital Content Editor, DDW